DeLano MC, Spampinato MV, Chang EY, et al. - A retrospective, multicenter study was conducted to compare 0.05 mmol/kg and 0.1 mmol/kg gadobenate in patients undergoing enhanced MRI of the central nervous system (CNS). Researchers included a total of 352 patients receiving 0.05 (n = 181) or 0.1 (n = 171) mmol/kg gadobenate. Researchers conducted a student's t-test for comparison of mean qualitative endpoint scores, Wilcoxon signed-rank test for comparison of lesion-to-brain ratio and contrast-to-noise ratio values; Wilcoxon rank-sum test for comparison of SI changes. It was shown that 0.05 mmol/kg gadobenate was non-inferior to 0.1 mmol/kg gadobenate for lesion visualization.